Company intelligence / Profile preview
Continuity Biosciences
Bradenton, Florida, United Statescontinuitybiosciences.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Focal Medical's iontophoresis device directed gemcitabine therapy for pancreatic cancer has received IND clearance from FDA with Phase 1b clinical trials expected to begin in 2025
- Therapeutic areas
- OncologyInfectious DiseasesImmunologyMetabolic Disorders
- Modalities
- DeviceCell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Houston Methodist HospitalUniversity of North Carolina at Chapel Hill
Beyond the preview
Go deeper on Continuity Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Continuity Biosciences.